Hepatitis B reactivation and immune check point inhibitors
- 10 September 2020
- journal article
- research article
- Published by Elsevier BV in Digestive and Liver Disease
- Vol. 53 (4), 452-455
- https://doi.org/10.1016/j.dld.2020.08.041
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Fatal Toxic Effects Associated With Immune Checkpoint InhibitorsJAMA Oncology, 2018
- Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infectionAsia-Pacific Journal of Clinical Oncology, 2018
- Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case seriesMelanoma Research, 2018
- Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling studyThe Lancet Gastroenterology & Hepatology, 2018
- Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitorsJournal of Hepatology, 2018
- Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapyAIDS, 2017
- HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanomaAnnals of Oncology, 2017
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialThe Lancet, 2017
- T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significanceCell Death & Disease, 2015
- Immune surveillance by the liverNature Immunology, 2013